<DOC>
	<DOCNO>NCT02536755</DOCNO>
	<brief_summary>Primary Objective : Evaluate long term skeletal response eliglustat adult patient successfully complete Phase 2 Phase 3 study . Secondary Objective : Evaluate safety eliglustat adult patient successfully complete Phase 2 Phase 3 study .</brief_summary>
	<brief_title>Skeletal Response Eliglustat Patients With Gaucher Disease</brief_title>
	<detailed_description>The duration study period per patient least 2 year .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>Inclusion criterion : The patient must successfully complete Phase 2 ( GZGD00304 ) Phase 3 study ( GZGD02507 , GZGD02607 GZGD03109 ) . Successful completion define patient enrol one mention study receive eliglustat end study complete endofstudy visit without discontinue withdrawn prematurely . The patient willing able provide sign informed consent prior protocolrequired procedure perform . Female patient childbearing potential must document negative pregnancy test prior enrollment receive eliglustat treatment . Female patient childbearing potential must willing practice true abstinence line prefer usual lifestyle , use medically accept form contraception ( either barrier method , condom diaphragm + spermicide , nonbarrier method oral , injected , implanted hormonal method , intrauterine device system ) receive eliglustat . Exclusion criterion : The patient unwilling comply requirement protocol . The patient receive investigational product ( eliglustat ) within 30 day prior enrollment . The patient receive miglustat within 6 month prior enrollment . The patient document prior esophageal varix liver infarction current liver enzyme ( alanine transaminase , aspartate aminotransferase ) total bilirubin &gt; 2 time upper limit normal unless patient diagnosis Gilbert Syndrome . The patient clinically significant disease , Gaucher disease , include cardiovascular , renal , hepatic , gastrointestinal , pulmonary , neurologic , endocrine , metabolic ( eg , hypokalemia , hypomagnesemia ) , psychiatric disease , medical condition , serious intercurrent illness may preclude participation study . The patient know following : cardiac disease ( congestive heart failure , recent acute myocardial infarction , bradycardia , heart block , ventricular arrhythmia ) , long QT syndrome , current treatment Class IA ( eg , quinidine ) Class III ( eg , amiodarone , sotalol ) antiarrhythmic medicinal product . The patient test positive human immunodeficiency virus ( HIV ) antibody , hepatitis C antibody , hepatitis B surface antigen . The patient history cancer within 6 month enrolment , exception basal cell carcinoma . Patient CYP 2D6 IM , EM URM take strong moderate CYP2D6 inhibitor concomitantly strong moderate CYP3A inhibitor Patient CYP2D6 PM take strong CYP3A inhibitor within 2 week prior enrolment . If female patient childbearing potential positive pregnancy test ( blood βHuman Chorionic Gonadotropin ( βHCG ) breast feed prior first dose eliglustat study , patient enroll study time , may rescreened end pregnancy , and/or longer breast feeding , provide rescreening take place end enrollment period . Women childbearing potential unwilling unable test pregnancy . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>